{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Myocardial Infarction",
            "NStudiesAvail": 430108,
            "NStudiesFound": 46,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 46,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Seung-Hwan Lee, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Absolute changes in global left ventricular ejection fraction (LVEF) as measured by SPECT 6 months after cell infusion"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Absolute changes in global LVEF by SPECT"
                        ],
                        "NCTId": [
                              "NCT01392105"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 10, 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "changes in myocardial metabolic activity 6 months after transplantation of autologous BM-MSCs (SPET assay)",
                              "Changes in left ventricular ejection fraction (LVEF) at 12 months after transplantation of autologous BM-MSCs."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "changes in myocardial metabolic activity",
                              "Changes in left ventricular ejection fraction (LVEF)"
                        ],
                        "NCTId": [
                              "NCT04421274"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Lian Ru Gao, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary endpoints were differences between the two treatments and from baseline to 4 months in quantitative myocardial metabolic and perfusion images, as measured by 18F-FDG positron emission tomography and 99 mTctetrofosmine single-photon imaging. Left ventricular ejection fraction is measured by 16-segment 2-D echocardiography."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Quantify myocardium metabolic and perfusion measured by F-18-fluorodeoxyglucose (F-18-FDG) postremission tomography (PET) and 99 mTctetrofosmine single-photon (SPET), as well as global left ventricular ejection fraction measured by echocardiography."
                        ],
                        "NCTId": [
                              "NCT01291329"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "Ken Borow, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 4, 2006"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Comparison of treatment adverse event rates between the 0.5, 1.6 and 5.0 million mesenchymal stem cells per kilogram dose cohorts and placebo groups."
                        ],
                        "NCTId": [
                              "NCT00114452"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Woei Shyu"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "TEAE incidences over the study period",
                              "SAE incidences over the study period",
                              "SUSAR incidences over the study period"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Treatment emergent adverse event (TEAE) as presented by MedDRA coding system",
                              "Incidence of Serious adverse event (SAE) as presented by MedDRA coding system",
                              "Incidence of Suspected and unexpected serious adverse reaction (SUSAR) as presented by MedDRA coding system"
                        ],
                        "NCTId": [
                              "NCT04056819"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 8, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
                              "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Major adverse cardiac events (MACE) endpoints of mortality",
                              "Major adverse cardiac events (MACE) endpoints of mortality",
                              "Major adverse cardiac events (MACE) endpoints of mortality",
                              "Major adverse cardiac events (MACE) endpoints of mortality",
                              "Re-infarction",
                              "Re-infarction",
                              "Re-infarction",
                              "Re-infarction",
                              "Target vessel revascularization (TVR)",
                              "Target vessel revascularization (TVR)",
                              "Target vessel revascularization (TVR)",
                              "Target vessel revascularization (TVR)",
                              "Heart failure hospitalization",
                              "Heart failure hospitalization",
                              "Heart failure hospitalization",
                              "Heart failure hospitalization"
                        ],
                        "NCTId": [
                              "NCT04340609"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Evgeny A Pokushalov, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Reduction in left ventricle systolic volume on 15% mesured by MRI"
                        ],
                        "NCTId": [
                              "NCT01394432"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Jeonghan Yoon, Ph.D. M.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Left ventricle ejection fraction (LVEF) measured 13 months after the cell treatment (MRI measurement)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "LVEF amount of change"
                        ],
                        "NCTId": [
                              "NCT01652209"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Antoni Bayes-Gen\u00eds, MD, PhD,FESC"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety measured with a combined endpoint of serious clinical events (death or rehospitalization due to any cause) and serious adverse reactions related to the investigational treatment."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Rate of death or rehospitalization due to any cause and / or adverse reactions related to the procedure / product under investigation."
                        ],
                        "NCTId": [
                              "NCT03798353"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "Sreenivas Kumar, MD, DM",
                              "Satya Gupta",
                              "R Keshava, MD, DM",
                              "Prakash VS, MD., DM"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "AE and ECG parameters"
                        ],
                        "NCTId": [
                              "NCT00883727"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Ken Borow, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 18, 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Change from Baseline in Cardiac Magnetic Resonance (CMR) imaging-determined End Systolic Volume (ESV) at Month 3"
                        ],
                        "NCTId": [
                              "NCT00877903"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Saule Abseitova, MD, Prof.",
                              "Daniyar Jumaniyazov, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The safety and tolerability of aMBMC intravenous administration during the six month study period as determined by major adverse events MACE endpoint"
                        ],
                        "NCTId": [
                              "NCT02672267"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [
                              "Lian Ru Gao, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The main safety endpoints was the first occurrence of a major adverse cardiovascular event (a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and hospitalization for unstable angina that led to urgent coronary revascularization within 12 months.",
                              "The main feasibility endpoints were defined as the change in LVEF, infarct size as determined by MRI and perfusion defect as assessed by MIBI SPECT from baseline to 6 months.",
                              "The main feasibility endpoints were defined as the change in infarct size",
                              "The main feasibility endpoints were defined as non significant perfusion defect"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Any composite of major adverse cardiovascular events",
                              "Checking patient LVEF",
                              "Checking patient infarct size",
                              "checking patient perfusion defect."
                        ],
                        "NCTId": [
                              "NCT04551443"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Changes in left ventricular ejection fraction from baseline to 12 months' by MRI"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Changes in left ventricular ejection fraction from baseline to 12 months'"
                        ],
                        "NCTId": [
                              "NCT03047772"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Armin Attar, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 1, 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The incidence of heart failure during the follow-up period."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Heart Failure"
                        ],
                        "NCTId": [
                              "NCT05043610"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "mpujol@med.miami.edu"
                        ],
                        "PointOfContactOrganization": [
                              "ISCI / University of Miami Miller School of Medicine"
                        ],
                        "PointOfContactPhone": [
                              "305-243-7273"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Marietsy pujol / Senior Regulatory Specialist"
                        ],
                        "PrimaryCompletionDate": [
                              "March 2, 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence (at one month post-catheterization) of any treatment-emergent serious adverse events, defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Participants With Treatment-emergent Serious Adverse Events (SAE)."
                        ],
                        "NCTId": [
                              "NCT02013674"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [
                              "Joshua M. Hare, MD",
                              "Gary Gerstenblith, MD",
                              "John V. Conte, MD",
                              "Steven P. Schulman, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "amendizabal@emmes.com"
                        ],
                        "PointOfContactOrganization": [
                              "EMMES Corporation"
                        ],
                        "PointOfContactPhone": [
                              "301-251-1161"
                        ],
                        "PointOfContactPhoneExt": [
                              "221"
                        ],
                        "PointOfContactTitle": [
                              "Adam Mendizabal"
                        ],
                        "PrimaryCompletionDate": [
                              "June 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Six-month post-CABG surgery serious adverse event (SAE) proportion of patients experiencing a composite of sustained ventricular arrhythmias, (lasting longer than 15 seconds), with hemodynamic compromise, sudden unexpected death at six months, ectopic tissue formation at 12 months by chest/abdomen/pelvis CT exam."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Patients With Serious Adverse Events"
                        ],
                        "NCTId": [
                              "NCT00587990"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [
                              "Chengxing Shen, Dr."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Possible adverse events, including adverse events that may occur during angiography and infusion of transplanted cells such as chest pain, arrhythmia, slow blood flow, myocardial injury, fever, allergic reaction, postoperative infection, etc."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety measured as the number of Major Adverse Cardiac Events (MACE)"
                        ],
                        "NCTId": [
                              "NCT03902067"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OverallOfficialName": [
                              "Piotr Musia\u0142ek, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Reduction of infarct size assessed in cardiac MRI during index hospitalization and in 6 month FU between two groups (active vs sham)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Reduction of infarct size"
                        ],
                        "NCTId": [
                              "NCT03404063"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OverallOfficialName": [
                              "Zhongmin Liu, Doctor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The change in Left ventricular ejection fraction (LVEF) % after the operation",
                              "The change in Left ventricular end diastolic volume (LVEDV) ml after the operation",
                              "The change in Left ventricular end systolic volume (LVESV) ml after the operation",
                              "The change in Stroke volume (SV) ml after the operation",
                              "The change in Left ventricular apex four-chamber end systolic diameter (LVESD) mm after the operation",
                              "The change in 6 minutes walking distance m after the operation"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Left ventricular ejection fraction",
                              "Left ventricular end diastolic volume",
                              "Left ventricular end systolic volume",
                              "Stroke volume",
                              "Left ventricular apex four-chamber end systolic diameter",
                              "6 minutes walking distance"
                        ],
                        "NCTId": [
                              "NCT04939077"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "amendizabal@emmes.com"
                        ],
                        "PointOfContactOrganization": [
                              "The EMMES Corporation"
                        ],
                        "PointOfContactPhone": [
                              "301 251 1161"
                        ],
                        "PointOfContactPhoneExt": [
                              "221"
                        ],
                        "PointOfContactTitle": [
                              "Adam Mendizabal"
                        ],
                        "PrimaryCompletionDate": [
                              "April 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation"
                        ],
                        "NCTId": [
                              "NCT01087996"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OverallOfficialName": [
                              "Nabil Dib, MD, MSc, FACC"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The safety and tolerability of aMBMC intravenous administration during the twelve month study period as determined by major adverse events MACE endpoint."
                        ],
                        "NCTId": [
                              "NCT01770613"
                        ]
                  },
                  {
                        "Rank": 23,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Change in global left ventricular ejection fraction (LVEF)measured by echocardiography.",
                              "Change in infarct size and myocardial viability within the infarcted region measured by emission computed tomography (ECT)."
                        ],
                        "NCTId": [
                              "NCT02666391"
                        ]
                  },
                  {
                        "Rank": 24,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD",
                              "Richard P Schwarz, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "amendizabal@emmes.com"
                        ],
                        "PointOfContactOrganization": [
                              "The EMMES Corporation"
                        ],
                        "PointOfContactPhone": [
                              "301-251-1161"
                        ],
                        "PointOfContactPhoneExt": [
                              "221"
                        ],
                        "PointOfContactTitle": [
                              "Adam Mendizabal, Biostatistician"
                        ],
                        "PrimaryCompletionDate": [
                              "August 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation"
                        ],
                        "NCTId": [
                              "NCT00768066"
                        ]
                  },
                  {
                        "Rank": 25,
                        "OverallOfficialName": [
                              "Ning K Zhang, MS"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 1, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "the incidence of adverse events (AEs) within 12 months, including death, nonfatal MI, stroke, hospitalization for worsening heart function, severe arrhythmias, repeated coronary intervention, stent thrombosis, coronary artery microvascular obstruction, immune system disorders, or ectopic tissue formation, was monitored and quantified. Laboratory assays, including biochemical assays, hematologic, tumor and immune indexes and Holter monitoring, were performed at the different follow-up times at 1 months-1 year. The trial will be monitored by a Data and Safety Monitoring Board (DSMB) and the trial will be discontinued in case of safety concerns."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The primary end point was safety in incidence of adverse events (AEs) within 12 months"
                        ],
                        "NCTId": [
                              "NCT02368587"
                        ]
                  },
                  {
                        "Rank": 26,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2030"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence (at one month post-catheterization) of any treatment-emergent serious adverse events (TE-SAEs), defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise), or atrial fibrillation."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of any treatment emergent serious adverse events (TE-SAEs)"
                        ],
                        "NCTId": [
                              "NCT02503280"
                        ]
                  },
                  {
                        "Rank": 27,
                        "OverallOfficialName": [
                              "jerome RONCALLI, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Evaluate safety and feasibility of transendocardial injection using the NogaStar XP Mapping Catheter with the MyostarTM Left Ventricular Injection Catheter of autologous MSC in subjects with chronic myocardial ischemia and left ventricular dysfunction"
                        ],
                        "NCTId": [
                              "NCT01076920"
                        ]
                  },
                  {
                        "Rank": 28,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "LVEF (left ventricular ejection fraction)"
                        ],
                        "NCTId": [
                              "NCT02504437"
                        ]
                  },
                  {
                        "Rank": 29,
                        "OverallOfficialName": [
                              "Kyriakos Anastasiadis, MD, PhD FETCS"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Major adverse cardiac and cerebrovascular events including death, postoperative myocardial infarction, need for revascularization, stroke, hospitalization for worsening heart failure, myocardial rupture, infectious myocarditis, or sustained ventricular arrhythmias.",
                              "Hypersensitivity reaction (fever, urticaria, hemolytic anemia, hypotension, immune thrombocytopenia)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "iMP-related adverse events",
                              "Hypersensitivity"
                        ],
                        "NCTId": [
                              "NCT01753440"
                        ]
                  },
                  {
                        "Rank": 30,
                        "OverallOfficialName": [
                              "Tambi Jarmi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 1, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of serious adverse events reported. SAEs will include delayed graft function (30 days post-transplant), difficult to control bleeding (intraoperative), sub-scapular kidney hematoma or arteriovenous fistula formation (24 hours postop), and development of stroke, myocardial infarction, or pulmonary embolism (1 year post-transplant)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Serious Adverse Events (SAEs)"
                        ],
                        "NCTId": [
                              "NCT04388761"
                        ]
                  },
                  {
                        "Rank": 31,
                        "OverallOfficialName": [
                              "Lian Ru Gao, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Including death from any cause; a composite of major adverse cardiovascular events of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death and hospitalization for unstable angina that led to urgent coronary revascularization;"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The primary end point was checking incidence of adverse events (AEs) within 12 months,"
                        ],
                        "NCTId": [
                              "NCT04551456"
                        ]
                  },
                  {
                        "Rank": 32,
                        "OverallOfficialName": [
                              "Reza Malekzadeh, M.D.",
                              "Hamid Goorabi, Phd",
                              "Mehdi Mohamadnejad, M.D.",
                              "Hossein Baharvand, Phd"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Chair",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2008"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Serum cholesterol and LDL levels"
                        ],
                        "NCTId": [
                              "NCT00515307"
                        ]
                  },
                  {
                        "Rank": 33,
                        "OverallOfficialName": [
                              "Guoping Lu, Doctor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The death rate of children in 28 days after their discharged from PICU",
                              "The Marshall Multiple Organ Dysfunction Score (MODS) assesses the same six organ systems using slightly different values for four grades of organ dysfunction. The total score, ranging from 0 to 24, arises from the sum of all single organ scores using the first measured value of the day. Intervals for the most abnormal value of each variable were constructed on a scale from 0 to 4 so that a value of 0 represented essentially normal function and was associated with an ICU mortality rate of < 5%, whereas a value of 4 represented marked functional derangement and an ICU mortality rate of > or = 50%.",
                              "The APPS is a 9-point score that is calculated by measuring the age, PaO2/FIO2 ratio, and plateau pressure at 24 h after the patient is diagnosed with moderate to severe ARDS and counting each one to 1-3. Since many variables are not needed for calculations, clinicians can easily predict the in-hospital mortality of mechanically ventilated patients with moderate to severe ARDS patients at bedside."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The death rate of children",
                              "Marshall Multiple Organ Dysfunction Score",
                              "the APPS score"
                        ],
                        "NCTId": [
                              "NCT04850469"
                        ]
                  },
                  {
                        "Rank": 34,
                        "OverallOfficialName": [
                              "Anthony Oliva, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Monitoring of events includes death, sustained/symptomatic ventricular tachycardia requiring intervention with inotropic support, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Monitor major adverse cardiac events"
                        ],
                        "NCTId": [
                              "NCT02398604"
                        ]
                  },
                  {
                        "Rank": 35,
                        "OverallOfficialName": [
                              "Bing Liu, M.D",
                              "Xiaozhong Zhang, M.D"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evidence for new clinical/biological abnormalities.",
                              "Major adverse coronary events (MACE) were defined as cardiac death, non-fatal myocardial infarction, or rehospitalization for acute coronary syndrome and for congestive heart failure."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number and nature of adverse events",
                              "Incidence of major adverse coronary events (MACE)"
                        ],
                        "NCTId": [
                              "NCT02439541"
                        ]
                  },
                  {
                        "Rank": 36,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The incidence of Treatment-Emergent Serious Adverse Events will be evaluated, including: sustained/symptomatic ventricular tachycardia requiring intervention with inotropic support; aggravation of heart failure; myocardial infarction; unplanned cardiovascular operation for cardiac tamponade; infection during the first month post-treatment; and death."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events."
                        ],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 37,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "JHare@med.miami.edu"
                        ],
                        "PointOfContactOrganization": [
                              "ISCI / University of Miami Miller School of Medicine"
                        ],
                        "PointOfContactPhone": [
                              "305-243-5579"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Joshua M. Hare, MD"
                        ],
                        "PrimaryCompletionDate": [
                              "August 28, 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of TE-SAEs is defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise), or any other potential late effects detected and corroborated by clinical presentation, laboratory investigations, image analysis and when necessary with biopsy from suspected target sites in the body."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)"
                        ],
                        "NCTId": [
                              "NCT01392625"
                        ]
                  },
                  {
                        "Rank": 38,
                        "OverallOfficialName": [
                              "Ahmed O Gaber, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Infusional toxicity will be assessed as the occurrence of either 1) two or more participants having deep vein thrombosis (Grade 2 thrombotic event); 2) any participant having evidence of the first-pass phenomenon of cells trapping in the lung as evidenced by (a) shortness of breath at rest, (b) requiring ventilator support, or (c) pulmonary edema with hypoxia requiring support; or 3) Grade 4 hypertension or hypotension; or 4) acute myocardial infarction; or 5) new onset congestive heart failure; or 6) capillary leak syndrome; or 7) acute kidney injury; or 8) biopsy-proven rejection."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants without any infusional toxicity, occurring within 24 hours of infusion."
                        ],
                        "NCTId": [
                              "NCT03478215"
                        ]
                  },
                  {
                        "Rank": 39,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 30, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Percentage of improvement in left ventricular ejection fraction (LVEF) on transthoracic echocardiography and cardiac magnetic resonance imaging (MRI)",
                              "Percentage of improvement of the final diastolic and systolic volumes on transthoracic echocardiography and cardiac MRI",
                              "Effect on viability, defined as a percentage of wall involvement, and improvement in segment-to-segment contractility measured with MRI",
                              "Incidence of ventricular arrhythmias defined as nonsustained ventricular tachycardia (NSTV) or high- or low-grade ventricular extrasystoles"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Left ventricular ejection fraction (LVEF)",
                              "Final diastolic and systolic volumes",
                              "Left ventricule viability",
                              "Ventricular arrhythmias"
                        ],
                        "NCTId": [
                              "NCT04011059"
                        ]
                  },
                  {
                        "Rank": 40,
                        "OverallOfficialName": [
                              "Oteh Maskon, MB Bch"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Change in LV ejection fraction as measured by echocardiogram and cardiac MRI after implantation"
                        ],
                        "NCTId": [
                              "NCT01720888"
                        ]
                  },
                  {
                        "Rank": 41,
                        "OverallOfficialName": [
                              "Ari Harjula, MD; PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2009"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Does a bone marrow transplantation therapy increase the ejection fraction of the heart measured with MRI, when compared with placebo treatment?"
                        ],
                        "NCTId": [
                              "NCT00418418"
                        ]
                  },
                  {
                        "Rank": 42,
                        "OverallOfficialName": [
                              "Guillermo Torre Amione, MD, PhD",
                              "Francois Haddad, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "bvrtovec@stanford.edu"
                        ],
                        "PointOfContactOrganization": [
                              "UMC Ljubljana"
                        ],
                        "PointOfContactPhone": [
                              "+3861 522 2844"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Prof. Dr. Bojan Vrtovec"
                        ],
                        "PrimaryCompletionDate": [
                              "April 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Left ventricular ejection fraction measured by echocardiography"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Heart Failure Mortality",
                              "Changes in Left Ventricular Ejection Fraction"
                        ],
                        "NCTId": [
                              "NCT00629018"
                        ]
                  },
                  {
                        "Rank": 43,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 30, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Outcome measures will be determined by cardiac MR, SPECT and PET monitoring to assess the left ventricular ejection fraction (%), left ventricle end-diastolic and end-systolic volumes (mL/m2), left ventricle mass (g/m2), infarct size (%), and the thickness of the dysfunctional wall (mm)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "ventricular remodeling"
                        ],
                        "NCTId": [
                              "NCT02323477"
                        ]
                  },
                  {
                        "Rank": 44,
                        "OverallOfficialName": [
                              "Nawara Mohamed Hashish, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Comparison of the implantation rates of all groups; the differentiated stem cell group, the undifferentiated stem cell group and the control group to assess the efficacy of differentiated and undifferentiated stem cell therapy in improving endometrial receptivity."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Implantation rate"
                        ],
                        "NCTId": [
                              "NCT01649752"
                        ]
                  },
                  {
                        "Rank": 45,
                        "OverallOfficialName": [
                              "Amanda Olson, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 30, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Statistical analyses of safety will be descriptive.",
                              "The comparison will be between the two groups of patients."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of adverse events",
                              "Change in left ventricular ejection fraction (LVEF)"
                        ],
                        "NCTId": [
                              "NCT02962661"
                        ]
                  },
                  {
                        "Rank": 46,
                        "OverallOfficialName": [
                              "Yawei Xu, MD,PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 1, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary outcome will evaluate the change in left ventricular function as measured by echocardiography and D-SPECT for left ventricular ejection fraction (LVEF).",
                              "The primary outcome will evaluate the change in infarct size as measured by D-SPECT."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change from baseline to 6 months follow-up in LVEF.",
                              "Change from baseline to 6 months follow-up in infarct size."
                        ],
                        "NCTId": [
                              "NCT03397095"
                        ]
                  }
            ]
      }
}